Madrigal's 15-Minute Chart Shows MACD Death Cross, Bearish Marubozu Pattern

Based on the 15-minute chart for Madrigal, a MACD Death Cross and a Bearish Marubozu pattern were observed on September 4, 2025 at 11:15. This suggests that the stock price has the potential to continue its downward trajectory, with sellers dominating the market and bearish momentum likely to persist.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has recently received a conditional marketing authorization for Rezdiffra from the European Commission, which treats adults with noncirrhotic MASH and moderate to advanced liver fibrosis. The stock has surged more than 8.5% since the announcement, reflecting Wall Street's bullish sentiment [1]. However, a recent analysis by Leerink Partners analyst Thomas Smith maintained a Buy rating on the stock without disclosing a price target, highlighting the significance of the approval [1].

Despite the positive news, a 15-minute chart for Madrigal on September 4, 2025, at 11:15, revealed a MACD Death Cross and a Bearish Marubozu pattern. This suggests that the stock price has the potential to continue its downward trajectory, with sellers dominating the market and bearish momentum likely to persist [2]. These technical indicators, combined with the recent regulatory approval, indicate a mixed market sentiment.

On the other hand, Sagimet Biosciences Inc. (NASDAQ:SGMT) has shown significant momentum as the FDA eases the path for MASH drug development. Denifanstat, the lead drug candidate of Sagimet, has shown promising Phase 2b data and is entering Phase 3 trials. The FDA's decision to accept a non-invasive liver stiffness scan as a valid surrogate endpoint has made it easier and faster to recruit patients for trials, potentially shaving years and millions of dollars off the clinical pathway [2]. This regulatory update has been priced into the stock, with shares rising over 10% on August 27, 2025, despite being down roughly 24% over the past month [2].

In conclusion, while Madrigal Pharmaceuticals faces bearish signals, the recent approval of Rezdiffra could pave the way for future growth. Meanwhile, Sagimet Biosciences is poised to benefit from the FDA's decision, which could significantly impact its stock performance. Investors should monitor both companies' progress closely, considering the potential impact of regulatory approvals and market sentiment.

References:
[1] https://finance.yahoo.com/news/leerink-partners-maintains-buy-madrigal-034955145.html
[2] https://seekingalpha.com/article/4817896-sagimet-gains-momentum-as-fda-eases-path-for-mash-drug-development